AstraZeneca Zegfrovy is now the center of a major oncology licensing agreement. AstraZeneca announced on July 14, 2026, that it has entered an exclusive global license agreement with Dizal Pharmaceutical Co., Ltd. for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor developed for patients with lung cancer. Under the agreement, AstraZeneca will acquire worldwide rights to develop and commercialize Zegfrovy.
Zegfrovy is already approved in the United States and China for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors carry EGFR exon 20 insertion mutations and whose disease has progressed on or after platinum-based chemotherapy. The drug’s addition gives AstraZeneca a differentiated, oral targeted therapy for a patient population that has historically had few treatment options.
Inside the AstraZeneca Zegfrovy Licensing Agreement
The scale of the unmet need behind this deal is significant. Approximately 80-85% of all lung cancer cases globally are classified as NSCLC. Within that group, roughly 10-15% of patients in the US and Europe, and 30-40% of patients in Asia, have EGFR-mutated NSCLC. Of those patients, about one in four carries an exon 20 insertion or other atypical mutation, a subset for which targeted treatment options remain limited.
Dave Fredrickson, Executive Vice President of the Oncology Haematology Business Unit at AstraZeneca, framed the acquisition as a natural extension of the company’s existing strength in EGFR-mutated disease. He said AstraZeneca is already a leader in treating EGFR-mutated lung cancer and is eager to add Zegfrovy to its portfolio for patients whose tumors carry exon 20 insertion mutations, calling it a differentiated oral treatment for patients with limited options worldwide.
Dr. Xiaolin Zhang, Chief Executive Officer of Dizal, echoed that sentiment, noting that AstraZeneca’s global reach and established lung cancer franchise will help extend a therapy discovered by Dizal’s scientists in China to patients around the world. He pointed out that Zegfrovy is currently the only oral targeted therapy approved in both the US and China for EGFR exon 20 insertion NSCLC following prior systemic therapy.
Zegfrovy’s Role in EGFR-Mutated Lung Cancer Treatment
Lung cancer remains the leading cause of cancer death among both men and women, accounting for roughly one-fifth of all cancer deaths worldwide. Around 75% of patients are diagnosed with advanced-stage NSCLC, which underscores the importance of durable, well-tolerated targeted options.
Financial Terms of the AstraZeneca Zegfrovy Deal
The transaction includes a substantial upfront payment plus milestone-based payments tied to development, regulatory, and commercial performance.
| Component | Value/Detail |
|---|---|
| Upfront payment to Dizal | $600 million |
| Potential milestone payments | Up to $900 million |
| Maximum total deal value | Up to $1.5 billion |
| Ongoing royalties to Dizal | Tiered, based on global Zegfrovy sales |
| Expected transaction close | Second half of 2026 |
| Conditions | Customary closing conditions and regulatory clearances |
| Impact on AstraZeneca 2026 guidance | None reported |
AstraZeneca’s Broader Lung Cancer Portfolio
Zegfrovy joins an already extensive AstraZeneca lung cancer lineup that includes Tagrisso and Iressa (gefitinib) for EGFR-mutated disease, Imfinzi (durvalumab) and Imjudo (tremelimumab) in immuno-oncology, Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) developed with Daiichi Sankyo, and Orpathys (savolitinib) developed with HUTCHMED. AstraZeneca is also a founding member of the Lung Ambition Alliance, a global coalition focused on accelerating innovation in lung cancer care.
